Tianjin Pharmaceutical Da Ren Tang's (SGX:T14, SHA:600329) attributable profit to owners surged to 2.23 billion yuan in 2024 from 986.7 million yuan a year earlier, according to a Friday filing with the Singapore Exchange.
Earnings per share rose to 2.90 yuan from 1.28 yuan in the comparable period.
Revenue declined 11% year over year to 7.31 billion yuan from 8.22 billion yuan, mainly due to a decrease in commercial sales.
The company declared a dividend of 1.28 yuan per share for the year ended Dec. 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.